Clearmind Medicine Files Japanese Patent, Gains IRB Approval, Stock Soars 40%
CMND•Clearmind Medicine shares jumped 40% after filing a Japanese patent for its MEAI-based non-hallucinogenic depression therapy and securing IRB approval from Johns Hopkins Medicine for its Phase I/II alcohol use disorder trial. Earlier this month the company enacted a 1-for-10 reverse stock split to meet Nasdaq’s $1 bid requirement.
1. Japanese Patent Filing Drives 40% Stock Rally
Clearmind Medicine filed a patent in Japan covering formulations of its proprietary MEAI molecule for a non-hallucinogenic depression therapy, triggering a roughly 40% share price increase.
2. IRB Approval for MEAI Alcohol Use Disorder Trial
Johns Hopkins Medicine’s IRB approved Clearmind’s Phase I/II clinical trial of CMND-100 for alcohol use disorder, confirming safety and tolerability at all dosing levels without serious side effects.
3. 1-for-10 Reverse Split Restores Nasdaq Compliance
Earlier this month Clearmind executed a 1-for-10 reverse stock split, boosting its per-share price above Nasdaq’s $1 minimum bid requirement and avoiding delisting risk.
4. Pipeline Expansion and Bullish Investor Sentiment
The company is extending its MEAI-based pipeline toward weight loss and other mental health treatments, while online investor sentiment turned extremely bullish and trading volumes surged, with technical forecasts targeting a breach of $10.
